Bioventus (BVS) Stock Forecast & Price Target

$10.67 +0.15 (+1.43%)

(As of 12/20/2024 05:15 PM ET)

Bioventus - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for Bioventus in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a buy rating for BVS.

Consensus Price Target

$15.00
40.58% Upside

According to the 3 analysts' twelve-month price targets for Bioventus, the average price target is $15.00. The highest price target for BVS is $17.00, while the lowest price target for BVS is $13.00. The average price target represents a forecasted upside of 40.58% from the current price of $10.67.

Get the Latest News and Ratings for BVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bioventus and its competitors.

BVS Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$15.00	$13.00	$10.33	$6.67
Forecasted Upside	40.58% Upside	13.04% Upside	-12.80% Downside	27.47% Upside
Consensus Rating	Moderate Buy	Buy	Buy	Buy

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

It’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.

>> Register for the Workshop Now

BVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bioventus Stock vs. The Competition

Type	Bioventus	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	40.58% Upside	25,828.56% Upside	14.54% Upside
News Sentiment Rating	Positive News See Recent BVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
12/17/2024	JPMorgan Chase & Co. 3 of 5 stars	Upgrade	Underweight ➝ Neutral	$12.00 ➝ $13.00	+16.59%
11/6/2024	Canaccord Genuity Group 1 of 5 stars	Boost Target	Buy ➝ Buy	$12.00 ➝ $15.00	+34.41%
9/27/2024	Craig Hallum 3 of 5 stars	Boost Target	Buy ➝ Buy	$12.00 ➝ $17.00	+53.85%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:00 PM ET.

BVS Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Bioventus is $15.00, with a high forecast of $17.00 and a low forecast of $13.00.
: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last twelve months. There is currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BVS shares.
: According to analysts, Bioventus's stock has a predicted upside of 40.58% based on their 12-month stock forecasts.
: Over the previous 90 days, Bioventus's stock had 1 upgrade by analysts.
: Bioventus has been rated by research analysts at Canaccord Genuity Group, Craig Hallum, and JPMorgan Chase & Co. in the past 90 days.
: Analysts like Bioventus less than other "medical" companies. The consensus rating score for Bioventus is 2.67 while the average consensus rating score for "medical" companies is 2.81. Learn more on how BVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Buy this coin BEFORE Inauguration Day … (Ad)

Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.

This could be his favorite coin.

This page (NYSE:BVS) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Stock Forecast & Price Target